Results 241 to 250 of about 208,218 (280)
Some of the next articles are maybe not open access.
The International Journal of Biochemistry & Cell Biology, 2007
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +2 more sources
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +2 more sources
Ranking the role of RANK ligand in apoptosis
Apoptosis, 2004Many members of tumor necrosis factor (TNF) superfamily are characterized by their ability to induce apoptosis once they bind in a homotrimeric manner to their cognate receptors. The receptor activator of nuclear factor-kappaB ligand (RANKL), a member of the TNF superfamily identified seven years ago, was originally described as a factor that induced ...
A C, Bharti, B B, Aggarwal
openaire +2 more sources
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure [PDF]
Circulation, 2005 Background— Persistent inflammation appears to play a role in the development of heart failure (HF). Osteoprotegerin (OPG), the receptor activator of nuclear factor-κB (RANK), and RANK ligand (RANKL) are newly discovered members of the tumor necrosis factor superfamily that are critical regulators in
Thor Ueland, Arne Yndestad, Erik Øie
exaly +3 more sources
Clinical Therapeutics, 2012
Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL).
David W Dempster, Andreas Grauer
exaly +3 more sources
Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL).
David W Dempster, Andreas Grauer
exaly +3 more sources
RANK ligand inhibition with denosumab for the management of osteoporosis
Expert Opinion on Biological Therapy, 2006Receptor activator of nuclear factor-kappaB ligand (RANKL) is a cytokine member of the tumour necrosis factor family that is the principal final mediator of osteoclastic bone resorption. It plays a major role in the pathogenesis of postmenopausal osteoporosis, as well bone loss associated with rheumatoid arthritis, metastatic cancer, multiple myeloma ...
E Michael Lewiecki
exaly +3 more sources
The affinity of human RANK binding to its ligand RANKL
Archives of Biochemistry and Biophysics, 2009Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL play critical roles in bone re-modeling, immune function, vascular disease and mammary gland development. To study the interaction of RANK and RANKL, we have expressed both extracellular domain of RANK and ectodomain of RANKL using Escherichia coli expression system.
Shiqian Zhang +2 more
exaly +3 more sources
Osteoprotegerin and rank ligand expression in prostate cancer
Urology, 2001To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Tissues from 28 patients with CaP and from 4 ...
J M, Brown +6 more
openaire +2 more sources
Bone metastasis in breast cancer: The story of RANK-Ligand
Journal of the Egyptian National Cancer Institute, 2012 The primary cellular mechanism responsible for osteolytic bone metastases is osteoclastic activation. Preclinical models have shown that breast cancer cells can produce parathyroid hormone-related protein (PTHrP), and other osteolytic molecules, which stimulate excessive osteoclastic bone resorption and establishment of osteolytic lesions.
Hatem A Azim
exaly +3 more sources
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, 2003Myeloma bone disease is due to interactions of myeloma cells with the bone marrow microenvironment, and is associated with pathologic fractures, neurologic symptoms and hypercalcemia. Adjacent to myeloma cells, the formation and activation of osteoclasts is increased, which results in enhanced bone resorption.
Orhan, Sezer +4 more
openaire +2 more sources
Clinical applications of RANK‐ligand inhibition
Internal Medicine Journal, 2009AbstractAn enhanced rate of bone remodelling fuelled by osteoclastogenesis mediates diseases such as osteoporosis, arthritic bone destruction, Paget’s disease and malignancy‐induced bone loss. Thus, the control of osteoclastogenesis is of major clinical importance.
openaire +2 more sources